Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Item

http://www.wikidata.org/entity/Q28264722

Q28264722

about

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs Etiology of cardiovascular disease in patients with schizophrenia: current perspectives The gene-gene interaction of INSIG-SCAP-SREBP pathway on the risk of obesity in Chinese children.The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk.DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells.Genetic variations in sterol regulatory element binding protein cleavage-activating protein (SCAP) are associated with blood pressure in overweight/obese Chinese children.Pharmacogenetics of antipsychotics.Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia Association of INSIG2 polymorphism with overweight and LDL in children.The promise and reality of pharmacogenetics in psychiatry Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.A potential mechanism underlying atypical antipsychotics-induced lipid disturbances Variants in doublecortin- and calmodulin kinase like 1, a gene up-regulated by BDNF, are associated with memory and general cognitive abilities.Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review.Pharmacogenetics in schizophrenia: a review of clozapine studies.Genetics of antipsychotic-induced weight gain: update and current perspectives.Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Pharmacogenetics of antipsychotic treatment response and side effects.Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells.Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study.Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.INSIG2 rs7566605 single nucleotide variant and global DNA methylation index levels are associated with weight loss in a personalized weight reduction program.Upstream genetic variant near INSIG2, influences response to carnitine supplementation in bipolar patients with valproate-induced weight gain.INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine.Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis.Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.Genetic variation in 117 myelination-related genes in schizophrenia: Replication of association to lipid biosynthesis genes

P2860

Q24630309-4A3C7407-FFE6-477F-9AAB-807B29BDC285 Q26778485-35AAC856-7447-4EA2-938C-C0FBD03494D2 Q30411895-E9920416-772C-48DC-A79B-0BA29744FD79 Q30990502-BAB899FC-F547-4962-BB24-6DC963D50F75 Q31059827-685A592D-2EF2-44D1-A958-907EA2B37931 Q33395532-D83E0E73-14E8-46F1-ABF1-C94B399167C0 Q33498169-9172D563-4CFE-4D64-BA37-DB776193E11C Q33708029-0E2287C4-D281-4894-95DE-8C0141D1CF9F Q33836837-12ADA8EE-4967-4076-9F74-8A90F01EBFF6 Q34145387-F9ECEE2B-00C7-4934-AA91-52B22EF5DD26 Q34660593-DA9EBC1C-EE16-4AB8-9DBD-167D86D1DF4E Q34995179-BE2AFC6C-F1F9-40C7-87F2-4B03AFE93B70 Q35226451-01C90FAF-5F52-4B43-9B95-9C322F150E27 Q35771833-BD6C8234-38C0-4BF7-87CE-C3956F6F9C9D Q37058653-12F6004C-CD91-4F40-94D3-0A37EDBA8221 Q37383009-235626A5-1D18-4386-AE7D-EBA6658215BB Q37648311-F1611A71-599B-4368-A3D7-CE14EC5E96B1 Q37917782-6E8C6B90-D663-4CEB-A7EF-4D7B704CB6BA Q37926893-0735382C-FECD-4848-BAC0-3226FB7C949B Q37952823-9FE8FF95-C43B-419E-92D2-003FDD05F24C Q37960512-4ED21481-BC03-4349-9A7B-E2F6083B7284 Q38083647-FF808058-E0DB-4FF7-98A5-BDA0525A903F Q38154175-F64F3414-0126-49EA-A9A5-2FF30E5129B6 Q38166456-F34CE5FB-815E-4B01-9C4A-8FE1C90C9342 Q38842714-2311EC41-60FF-4D87-96A9-4A0BC6B6E094 Q40663726-5D915C8B-238F-48AC-A4D3-B12DF053C08B Q41541889-8DA0BF52-873B-4E71-9FE2-D0FAA3BC0388 Q43053801-EF6BCBEF-6393-47C6-AF1E-0700D54414AB Q43067624-B35D26A9-5E88-4BEC-9669-FB9DA222F1F3 Q43299076-9255EA0A-5F54-4A60-82C4-F31AA92EDA76 Q46117105-3912368C-05E9-43B1-BE93-42A7D74AEE91 Q47176455-A1940192-068E-4E8F-A793-37F653621FC8 Q47182175-8D77B67F-EF91-435F-9DD9-8805DD2F9DEC Q47255631-9D4B05C9-E290-4954-9027-90F4009B704C Q47628101-B0579850-587D-4911-A75C-D5887CCB416D Q48909259-112D7CF6-09DB-48EA-8127-89D16136E582 Q49024766-6103A304-2674-47CD-B1E3-4638419DA80C Q49481418-767EEFE8-EEA8-4255-9DBE-FDE6D776DC44 Q50527728-2EF47FEB-C7EB-4E7B-B69F-4576F9807591 Q56888533-A236D091-2B8D-412D-BEF5-4CDE943D88E1

P2860

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Item

http://www.wikidata.org/entity/Q28264722

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu